James JD - ELYM Old Gen VP
Insider
James JD is Gen VP of ELYM Old
| Age | 58 |
| Phone | 877 354 3689 |
| Web | https://eliemtx.com |
ELYM Old Management Efficiency
The company has return on total asset (ROA) of (0.2454) % which means that it has lost $0.2454 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3835) %, meaning that it created substantial loss on money invested by shareholders. ELYM Old's management efficiency ratios could be used to measure how well ELYM Old manages its routine affairs as well as how well it operates its assets and liabilities.ELYM Old currently holds 349 K in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. ELYM Old has a current ratio of 17.13, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about ELYM Old's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| RA MSc | Pharvaris BV | 44 | |
| Mark Wallet | Century Therapeutics | N/A | |
| Niels Svenstrup | PepGen | 55 | |
| Thomas Shenk | Pmv Pharmaceuticals | 77 | |
| George Eldridge | Aerovate Therapeutics | 62 | |
| Joseph Zakrzewski | AN2 Therapeutics | 63 | |
| Michael Pitzner | Molecular Partners AG | N/A | |
| Maria Mancini | Champions Oncology | N/A | |
| Abhinav Shukla | Shattuck Labs | ||
| Kristina Masson | Acrivon Therapeutics, Common | 44 | |
| Thomas Schwerzmann | Molecular Partners AG | N/A | |
| Peng MD | Pharvaris BV | 47 | |
| Timothy MBA | Aerovate Therapeutics | 63 | |
| Paul MD | AN2 Therapeutics | 54 | |
| Anne Lesage | Pharvaris BV | 64 | |
| Dr MBA | MediciNova | 60 | |
| Guizhong Liu | Adagene | 54 | |
| Leila MD | Pmv Pharmaceuticals | 61 | |
| Hunter MD | Aerovate Therapeutics | 59 | |
| Annick Deschoolmeester | Pharvaris BV | 52 | |
| Gregory Russotti | Century Therapeutics | 58 | |
Management Performance
| Return On Equity | -0.38 | |||
| Return On Asset | -0.25 |
ELYM Old Leadership Team
Elected by the shareholders, the ELYM Old's board of directors comprises two types of representatives: ELYM Old inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ELYM. The board's role is to monitor ELYM Old's management team and ensure that shareholders' interests are well served. ELYM Old's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ELYM Old's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Erin Lavelle, COO VP | ||
| MD MBA, Chief Officer | ||
| James JD, Gen VP | ||
| Jo PalmerPhillips, Chief Officer | ||
| Andrew MD, Principal Chairman | ||
| Valerie Morisset, Chief Development | ||
| Emily Pimblett, Principal Officer | ||
| BAO BCh, President CEO | ||
| Susan MS, VP Affairs | ||
| Robert MBA, CEO Pres | ||
| MBA MD, Interim Officer | ||
| Nishi MD, Senior Development |
ELYM Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ELYM Old a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.38 | |||
| Return On Asset | -0.25 | |||
| Current Valuation | 23.84 M | |||
| Shares Outstanding | 67.06 M | |||
| Shares Owned By Insiders | 10.38 % | |||
| Shares Owned By Institutions | 77.67 % | |||
| Number Of Shares Shorted | 1.15 M | |||
| Price To Book | 0.99 X | |||
| EBITDA | (13.65 M) | |||
| Net Income | (35.12 M) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Other Consideration for investing in ELYM Stock
If you are still planning to invest in ELYM Old check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ELYM Old's history and understand the potential risks before investing.
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |